In previous proof-of-concept work, we demonstrated that STAR2, a nonameric TNFR2-specific variant of mouse TNF, could not only safely expand Tregs in vivo but also protect allo-HCT recipients from acute GvHD while sparing anti-lymphoma and anti-infectious properties of transplanted allogeneic Tcons (8). This evidence concerns the gene TNFRSF1B and lymphoma.